Freedom SOLO Stentless Heart Valve Study

Phase 3

Completed

• Conditions: Aortic Insufficiency; Aortic Stenosis
• Interventions: Device: Freedom SOLO Stentless Heart Valve

• Registration Number: NCT01115907
• Lead Sponsor: Sorin Group USA, Inc.

Brief Summary

The purpose of this clinical investigation is to demonstrate the safety and effectiveness of the Freedom SOLO heart valve.

Detailed Description

The SOLO clinical investigation is a prospective, non-randomized, multicenter trial of the SOLO Freedom heart valve implanted in patients requiring aortic valve replacement.

Study Timeline

• Study First Submitted: 2010-04-29
• Study First Submitted QC: 2010-04-30
• Study First Posted: 2010-05-04
• Study Start: 2010-12
• Primary Completion: 2014-10
• Study Completion: 2014-10
• Status Verified: 2015-01
• Last Update Submitted: 2015-01-22
• Last Update Posted: 2015-01-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 251

Inclusion Criteria

• The subject is male or female 18 years old or older.
• The subject or subject's legal representative is willing to sign the informed consent.
• The subject which preoperative evaluation indicated the need for native or prosthetic aortic valve replacement.
• Any subject amenable to aortic valve replacement with biological prosthesis should be enrolled in the study, even in conjunction with valve repair, coronary artery bypass grafting and other procedures.
• The subject is located in a geographic location that will enable the subject to return to the study site for all follow-up examinations (i.e. geographically stable).
• Subject will be available to the investigator(s) for postoperative follow-up beyond one year.

Exclusion Criteria

• The subject has preexisting valve prosthesis in the mitral, pulmonary or tricuspid position.
• The subject requires a double or multiple valve replacement (a valve repair is not considered an exclusion criterion).
• The subject has a previously implanted SOLO valve, within the clinical study, that requires replacement.
• The subject has active endocarditis or myocarditis.
• The subject is or will be participating in a concomitant research study of an investigational product.
• The subject is a minor, drug abuser, alcohol abuser, prison inmate, institutionalized, or is unable to give informed consent.
• The subject has a major or progressive non-cardiac disease that, in the investigator's experience, results in a life expectancy of less than 1 year, or the implant of the device produces an unacceptable increased risk to the subject.
• The subject is pregnant, planning to become pregnant or lactating.
• The subject has a congenital bicuspid aortic valve.
• The subject is known to be noncompliant or is unlikely to complete the study.
• The subject is undergoing renal dialysis for chronic renal failure or has been diagnosed with hyperparathyroidism.
• The subject has had an acute preoperative neurological deficit, myocardial infarction, or cardiac event that has not returned to baseline or stabilized ≥30 days prior to the planned valve implant surgery.
• The subject has extensive calcification of the aortic root where removal of the calcified tissue cannot be achieved.
• The subject has a significantly dilated aortic root that is not surgically corrected.
• The subject requires replacement of the aortic root / full root procedure.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Freedom SOLO stentless valve implant	Freedom SOLO Stentless Heart Valve	Appropriate subjects will receive the Freedom SOLO stentless valve implant as a replacement for a diseased or damaged native or prosthetic aortic valve.

Primary Outcome Measures

Name	Time	Method
Safety will be determined by incidence rate of adverse events	1 year	The complication and survival rates for the SOLO valve are comparable to appropriate historical controls manifested as objective performance criteria (OPCs) and to that reported in the literature for other stentless bioprostheses and stented pericardial valves.

Secondary Outcome Measures

Name	Time	Method
Efficacy will be determined by hemodynamics	1 year	The hemodynamic performance of the SOLO valve will be compared to that reported in the literature for other stentless bioprostheses and stented pericardial valves.
Effectiveness will be determined by NYHA Classification comparisons	1 year	Clinically significant improvement in overall patient condition by comparison of preoperative and postoperative NYHA functional classifications.

Trial Locations

Locations (15)

London Health Sciences Centre; 🇨🇦 London, Ontario, Canada

St. Vincent Heart Center; 🇺🇸 Indianapolis, Indiana, United States

Cleveland Clinic Foundation; 🇺🇸 Cleveland, Ohio, United States

The Valley Hospital; 🇺🇸 Ridgewood, New Jersey, United States

University of Bristish Columbia St. Paul Hospital; 🇨🇦 Vancouver, British Columbia, Canada

St. Boniface Hospital; 🇨🇦 Winnipeg, Manitoba, Canada

Cedars-Sinai Medical Center; 🇺🇸 Los Angeles, California, United States

Emory University; 🇺🇸 Atlanta, Georgia, United States

Oakwood Hospital; 🇺🇸 Dearborn, Michigan, United States

The Toledo Hospital; 🇺🇸 Toledo, Ohio, United States

Foothills Medical Centre; 🇨🇦 Calgary, Alberta, Canada

Lankenau Medical Center; 🇺🇸 Wynnewood, Pennsylvania, United States

Institut Universitaire de Cardiologie et de Pneumologie de Québec; 🇨🇦 Quebec, Canada

Hospital of the University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

University of Alberta Hospital; 🇨🇦 Edmonton, Alberta, Canada